Alex Slanix Paul reported grant involving 11,000 derivative units of ProMIS Neurosciences Inc. at $0.00 for $0 on May 20, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 22, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
11,000Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
11,000Direct
Trade date
May 20, 2026Grant
Filed
May 22, 2026, 4:30 PM ET2-day reporting delay
Accession
0001104659-26-065755Code A · Transaction 383559
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 20, 2026Grant5,500$0.00$0Trade 383558
2 transaction rows in this filing. Joint filers share the same rows.

PMN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PMN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +4.3%1w ago −3.7%1d ago −3%
Returns since7d −1.5%30d −4%90d +34%180d1y

Footnotes in full

F1: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. F2: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.